logo
Twitter
Discord
Email
logo
Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

NYSE•PBH
CEO: Mr. Ronald M. Lombardi CPA
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 2005-02-10
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Contact Information
660 White Plains Road, Suite 250, Tarrytown, NY, 10591, United States
914-524-6800
www.prestigebrands.com
Market Cap
$3.05B
P/E (TTM)
15.1
31.6
Dividend Yield
--
52W High
$90.04
52W Low
$57.25
52W Range
14%
Rank52Top 60.9%
3.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2026 Data

Revenue

$274.11M-3.33%
4-Quarter Trend

EPS

$0.86-21.82%
4-Quarter Trend

FCF

$55.38M-18.28%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Operating Cash Flow Strong Net cash provided by operations $136.5M for six months, increasing $11.9M year-over-year, supporting liquidity.
North American Margin Gain NA segment gross margin rose to 55.6% for three months, driven by favorable product mix shift offsetting revenue decline.
Diluted EPS Decreased Diluted EPS $1.81 for six months, decreasing $0.25 from $2.06 reported in the prior comparable period.
Cash Position Growth Cash equivalents reached $119.1M as of September 30, 2025, showing an increase of $21.2M since March 31, 2025.

Risk Factors

Consolidated Revenue Contraction Total revenues $523.6M for six months, declining 5.0%, primarily due to significant sales decrease in Eye & Ear Care.
Effective Tax Rate Spike Effective tax rate jumped to 38.9% (3M) from 24.1% due to establishing a taxable presence in a new state.
Customer Concentration Risk Walmart accounted for 20% of gross revenues for the three months ended September 30, indicating high customer dependence.
International Margin Pressure International segment gross profit decreased 8.6% (3M) due to increased inflation costs and adverse product mix.

Outlook

Corporate Lease Extension Entered third lease amendment extending corporate headquarters lease term in Tarrytown, New York, to December 31, 2037.
Share Repurchase Remaining $138.7M remains authorized for common stock repurchase under the $300.0M plan as of September 30, 2025.
Debt Covenants Compliance Management anticipates compliance with all financial and restrictive debt covenants over the next twelve months of operations.
Unvested Stock Compensation $16.1M in unrecognized RSU/PSU costs expected to be recognized over a weighted average period of 2.1 years.

Peer Comparison

Revenue (TTM)

Perrigo Company plcPRGO
$4.28B
-2.5%
Concentra Group Holdings Parent, Inc.CON
$2.09B
+11.4%
Privia Health Group, Inc.PRVA
$2.04B
+19.0%

Gross Margin (Latest Quarter)

Apellis Pharmaceuticals, Inc.APLS
94.6%
+11.6pp
Tarsus Pharmaceuticals, Inc.TARS
93.0%
-0.3pp
Ultragenyx Pharmaceutical Inc.RARE
82.5%
-2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IMVT$4.68B-10.0-84.9%0.0%
INDV$4.40B26.5-60.4%3.7%
TARS$3.46B-42.7-26.3%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.9%
Flat Growth
4Q Net Income CAGR
-11.6%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$1.16
|
Revenue:$286.93M
Reports
All Years
  • Form 10-Q - Q2 2026

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $274.11M-3.3%
    |
    EPS: $0.86-21.8%
    Miss
  • Form 10-Q - Q1 2026

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $249.53M-6.6%
    |
    EPS: $0.96-2.0%
    Miss
  • Form 10-K - FY 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $1.14B+1.1%
    |
    EPS: $4.32+2.6%
    Beat
  • Form 10-Q - Q3 2025

    Period End: Dec 31, 2024|Filed: Feb 6, 2025|
    Revenue: $290.32M+2.7%
    |
    EPS: $1.23+15.0%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $283.55M-1.0%
    |
    EPS: $1.10+1.9%
    Meet
  • Form 10-Q - Q1 2025

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $267.14M-4.4%
    |
    EPS: $0.98-8.4%
    Beat
  • Form 10-K - FY 2024

    Period End: Mar 31, 2024|Filed: May 15, 2024|
    Revenue: $1.13B-0.2%
    |
    EPS: $4.21+355.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Dec 31, 2023|Filed: Feb 8, 2024|
    Revenue: $282.74M+2.6%
    |
    EPS: $1.07+1.9%
    Meet